The results presented here confirm the now well-established observation that the majority (up to around 80%) of GISTs harbor KIT mutations, and the rapid translation of these mutational data into effective targeted kinase inhibitor therapies has borne out their importance in GIST pathogenesis [2, 29]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.